SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950135-03-003090
Filing Date
2003-05-15
Accepted
2003-05-15 12:53:41
Documents
7
Period of Report
2003-03-31

Document Format Files

Seq Description Document Type Size
1 ANTIGENICS INC. b46494age10vq.htm 10-Q 190700
3 EX-10.1 AIA DOCUMENT DATED 3/4/03 b46494agexv10w1.txt EX-10.1 62518
4 EX-10.2 LICENSE AGREEMENT DATED 5/25/01 b46494agexv10w2.txt EX-10.2 64166
5 EX-99.1 RISK FACTORS b46494agexv99w1.txt EX-99.1 33213
6 EX-99.2 CERTIFICATION OF CHIEF EXECUTIVE OFFICER b46494agexv99w2.txt EX-99.2 1064
7 EX-99.3 CERTIFICATION OF CHIEF FINANCIAL OFFICER b46494agexv99w3.txt EX-99.3 1105
8 COURTESY PDF b46494age10vqxpdfy.pdf 10-Q 571699
  Complete submission text file 0000950135-03-003090.txt   926815
Mailing Address 630 FIFTH AVENUE SUITE 2170 NEW YORK NY 10111
Business Address 630 FIFTH AVENUE SUITE 2170 NEW YORK NY 10111 2123324774
ANTIGENICS INC /DE/ (Filer) CIK: 0001098972 (see all company filings)

IRS No.: 061562417 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-29089 | Film No.: 03702718
SIC: 2836 Biological Products, (No Diagnostic Substances)